High Growth Tech Stocks to Watch in February 2025

Simply Wall St.
02-03

As global markets navigate a complex landscape marked by fluctuating economic indicators and competitive pressures in the technology sector, investors are closely watching key indices like the Nasdaq Composite, which recently experienced significant volatility due to emerging AI developments. In this environment, identifying promising high-growth tech stocks involves assessing companies that can effectively leverage innovation and adapt to shifting market dynamics while maintaining robust earnings potential.

Top 10 High Growth Tech Companies

Name Revenue Growth Earnings Growth Growth Rating
Shanghai Baosight SoftwareLtd 21.82% 25.22% ★★★★★★
Seojin SystemLtd 35.41% 39.86% ★★★★★★
Clinuvel Pharmaceuticals 21.39% 26.17% ★★★★★★
Ascelia Pharma 76.15% 47.16% ★★★★★★
Medley 20.95% 27.32% ★★★★★★
TG Therapeutics 29.48% 43.58% ★★★★★★
Fine M-TecLTD 36.52% 135.02% ★★★★★★
Initiator Pharma 73.95% 31.67% ★★★★★★
Dmall 29.53% 88.37% ★★★★★★
Delton Technology (Guangzhou) 20.25% 29.52% ★★★★★★

Click here to see the full list of 1230 stocks from our High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Bonesupport Holding

Simply Wall St Growth Rating: ★★★★★★

Overview: Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK22.93 billion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, which contributed SEK814.46 million.

Bonesupport Holding AB, a company in the high-growth tech sector, is showcasing robust potential with its innovative CERAMENT products. Recent clinical studies have demonstrated significant advantages of CERAMENT in treating bone infections, leading to a remarkable increase in 5-year survival rates for patients compared to standard treatments. Financially, BONEX is outpacing industry growth with an annual revenue increase projected at 33.8% and earnings expected to surge by 73.1% annually. This performance starkly contrasts the broader Swedish market's growth rates of just 1.1% for revenue and 13.4% for earnings per year, positioning Bonesupport well above average forecasts and highlighting its strong market presence driven by pioneering medical solutions.

  • Delve into the full analysis health report here for a deeper understanding of Bonesupport Holding.
  • Examine Bonesupport Holding's past performance report to understand how it has performed in the past.

OM:BONEX Earnings and Revenue Growth as at Feb 2025

Zhejiang Huace Film & TV

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zhejiang Huace Film & TV Co., Ltd. is involved in the production, distribution, and derivative of film and television dramas both in China and internationally, with a market capitalization of CN¥14.15 billion.

Operations: Huace Film & TV generates revenue primarily through the production and distribution of film and television content. The company operates within China as well as in international markets, leveraging its expertise in drama series.

Zhejiang Huace Film & TV, amidst a volatile market, is set to outpace its peers with an expected annual revenue growth of 21% and earnings growth of 30.7%. Despite recent challenges, including a significant earnings dip last year, the company's aggressive R&D investment strategy positions it for potential recovery and innovation in the entertainment sector. Notably, its recent dividend affirmation reflects a commitment to shareholder returns even in turbulent times. This blend of strategic financial management and robust growth projections could make Zhejiang Huace Film & TV an interesting entity in the evolving tech landscape of China's entertainment industry.

  • Click here to discover the nuances of Zhejiang Huace Film & TV with our detailed analytical health report.
  • Learn about Zhejiang Huace Film & TV's historical performance.

SZSE:300133 Revenue and Expenses Breakdown as at Feb 2025

Basler

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Basler Aktiengesellschaft specializes in developing, manufacturing, and selling digital cameras for professional users both in Germany and internationally, with a market capitalization of €249.63 million.

Operations: The company generates revenue primarily from its camera segment, which reported €182.31 million.

Amidst a backdrop of executive reshuffling and promising financial forecasts, Basler AG is poised for transformative growth. With the appointment of Ines Brückel as CFO, effective January 2025, the company strengthens its leadership with expertise in finance and technology. This strategic move coincides with an encouraging financial performance; despite a net loss reduction from EUR 17.52 million to EUR 6.68 million year-over-year, Basler's revenue growth forecast stands at a robust 10.8% annually. Moreover, earnings are expected to surge by an impressive 113.84% per year, signaling strong future prospects in the competitive tech landscape where innovation and agile management are key drivers of success.

  • Take a closer look at Basler's potential here in our health report.
  • Explore historical data to track Basler's performance over time in our Past section.

XTRA:BSL Revenue and Expenses Breakdown as at Feb 2025

Summing It All Up

  • Click through to start exploring the rest of the 1227 High Growth Tech and AI Stocks now.
  • Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
  • Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Contemplating Other Strategies?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OM:BONEX SZSE:300133 and XTRA:BSL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10